Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke

American Journal of Cardiology

Volumn 112, Issue 8, 2013, Pages 1230-1234

  Dinicolantonio, James J ^a   Lavie, Carl J ^b,c   Fares, Hassan ^b   Menezes, Arthur R ^b   O'Keefe, James H ^d   Bangalore, Sripal ^e   Messerli, Franz H ^f  

^a Wegmans Pharmacy   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG INDUCED HEADACHE; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART INFARCTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ASPIRIN; HUMANS; PLATELET AGGREGATION INHIBITORS; SECONDARY PREVENTION; STROKE; TETRAZOLES; VASODILATOR AGENTS;

EID: 84884903012     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.05.067     Document Type: Article

References (24)

1. C.J. Murray, and A.D. Lopez Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study Lancet 349 1997 1436 1442
2. P.M. Rothwell, and C.P. Warlow Timing of TIAs preceding stroke: time window for prevention is very short Neurology 64 2005 817 820
3. S.T. Pendlebury, and P.M. Rothwell Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis Lancet Neurol 8 2009 1006 1018
4. A. Algra, and J. van Gijn Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia J Neurol Neurosurg Psychiatry 60 1996 197 199
5. A. Algra, and J. van Gijn Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin J Neurol Neurosurg Psychiatry 66 1999 255
6. J. He, P.K. Whelton, B. Vu, and M.J. Klag Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials JAMA 280 1998 1930 1935
7. L.F. Zhang, J. Yang, Z. Hong, G.G. Yuan, B.F. Zhou, L.C. Zhao, Y.N. Huang, J. Chen, Y.F. Wu Collaborative Group of China Multicenter Study of Cardiovascular Epidemiology Proportion of different subtypes of stroke in China Stroke 34 2003 2091 2096
8. Q.D. Yang, Q. Niu, Y.H. Zhou, Y.H. Liu, H.W. Xu, W.P. Gu, F.F. Tian, Y.Q. Xie, L. Zhang, and J. Xia Incidence of cerebral hemorrhage in the Changsha community. A prospective study from 1986 to 2000 Cerebrovasc Dis 17 2004 303 313
9. J.H. Lee, S.Y. Park, Y.W. Shin, K.W. Hong, C.D. Kim, S.M. Sung, K.Y. Kim, and W.S. Lee Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion Brain Res 1082 2006 182 191
10. K. Schror The pharmacology of cilostazol Diabetes Obes Metab 4 Suppl 2 2002 S14 S19
11. F. Gotoh, H. Tohgi, S. Hirai, A. Terashi, Y. Fukuuchi, E. Otomo, Y. Shinohara, E. Itoh, T. Matsuda, T. Sawada, T. Yamaguchi, K. Nishimaru, and Y. Ohashi Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction J Stroke Cerebrovasc Dis 9 2000 147 157
12. R.W. Becker, E. Lusis, R.L. Sohn, and R.A. Kline Effects of cilostazol on human venous smooth muscle Ann Vasc Surg 19 2005 393 397
13. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P.A. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, and D. Moher The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
14. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, and H.J. McQuay Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
15. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
16. J.P. Higgins, and S. Green Cochran Handbook for Systematic Review of Interventions: Assessing Risk of Bias in Included Studies 5.0.0 ed. 2008 John Wiley & Sons, Inc Hoboken
17. Y. Shinohara, Y. Katayama, S. Uchiyama, T. Yamaguchi, S. Handa, K. Matsuoka, Y. Ohashi, N. Tanahashi, H. Yamamoto, C. Genka, Y. Kitagawa, H. Kusuoka, K. Nishimaru, M. Tsushima, Y. Koretsune, T. Sawada, C. Hamada CSPS 2 group Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial Lancet Neurol 9 2010 959 968
18. Y. Huang, Y. Cheng, J. Wu, Y. Li, E. Xu, Z. Hong, Z. Li, W. Zhang, M. Ding, X. Gao, D. Fan, J. Zeng, K. Wong, C. Lu, J. Xiao, C. Yao Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention cooperation investigators Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study Lancet Neurol 7 2008 494 499
19. Y.S. Lee, H.J. Bae, D.W. Kang, S.H. Lee, K. Yu, J.M. Park, Y.J. Cho, K.S. Hong, D.E. Kim, S.U. Kwon, K.B. Lee, J.H. Rha, J. Koo, M.G. Han, S.J. Lee, J.H. Lee, S.W. Jung, B.C. Lee, and J.S. Kim Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial Cerebrovasc Dis 32 2011 65 71
20. J.J. Guo, E. Xu, Q.Y. Lin, G.L. Zeng, and H.F. Xie Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke Neurosci Bull 25 2009 383 390
21. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
22. H.C. Diener, J. Bogousslavsky, L.M. Brass, C. Cimminiello, L. Csiba, M. Kaste, D. Leys, J. Matias-Guiu, H.J. Rupprecht MATCH investigators Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial Lancet 364 2004 331 337
23. O.R. Benavente, R.G. Hart, L.A. McClure, J.M. Szychowski, C.S. Coffey, and L.A. Pearce Effects of clopidogrel added to aspirin in patients with recent lacunar stroke N Engl J Med 367 2012 817 825
24. P. Verro, P.B. Gorelick, and D. Nguyen Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis Stroke 39 2008 1358 1363